Better Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Better Therapeutics, Inc.

Better Therapeutics, Inc. (ticker: BTTX) is a U.S.-based digital health company that has been listed on the NASDAQ market in the United States. The company was founded in 2015, originally as Nutrition Development Group LLC, later renamed Farewell LLC and then Better Therapeutics LLC, before becoming a Delaware corporation in 2020. Its headquarters are in San Francisco, California. Better Therapeutics develops prescription digital therapeutics (PDTs): regulated, software-based therapies designed to deliver behavioral intervention through a mobile application and support durable changes in patient behavior. The company’s core focus has been cardiometabolic disease, a large and clinically important area that includes conditions such as type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, NASH, and chronic kidney disease. Its business model is built around a proprietary PDT platform and a therapeutic approach based on cognitive behavioral therapy. The best-known product associated with the company is AspyreRx, a prescription digital therapy for type 2 diabetes that has received FDA authorization. More broadly, Better Therapeutics has positioned itself as a technology-enabled healthcare company targeting the root causes of chronic disease rather than only treating symptoms. From a competitive standpoint, Better Therapeutics operates in an early-stage and highly specialized segment at the intersection of software, behavioral medicine, and chronic disease management. Its investment case has historically rested on several differentiators: a drug-free treatment option, delivery through smartphones, the potential to scale more efficiently than traditional care models, and the possibility of improving adherence and outcomes while lowering total healthcare costs. At the same time, the company has faced significant execution risk. Prescription digital therapeutics require clinical validation, regulatory approval, payer adoption, and commercial traction, all of which can take time and capital. Competition is also rising across digital diabetes care and broader digital therapeutics. Recent public disclosures indicate a stressed corporate situation. In March 2024, Better Therapeutics announced that it would seek strategic alternatives, including a possible wind-down or assignment for the benefit of creditors, and noted that it would be delisted from Nasdaq. That development materially changed the company’s profile and suggests severe financial and operational pressure. For equity investors, the name should therefore be viewed as a distressed, event-driven healthcare situation rather than a conventional growth story. In that context, SEC filings, including insider Form 4 activity, remain important for monitoring governance, ownership changes, and any potential restructuring path.